Cytolysis in an elderly patient treated with dabigatran etexilate;Cytolyse hépatique sous dabigatran étexilate chez un sujet âgé

Therapie

Volumn 68, Issue 5, 2013, Pages 332-334

  Fulcrand, Julie ^a   Lerooy, Alexandre ^b   Giraud, Jean ^b   Cailliau, Antoine ^b   Delrot, Cédric ^b   Petitpain, Nadine ^c   Auffret, Marine ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CENTRE HOSPITALIER DE VALENCIENNES   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Adverse effect; Cytolysis; Dabigatran etexilate

Indexed keywords

DABIGATRAN ETEXILATE; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

AGED; CYTOLYSIS; HUMAN; LETTER; PRIORITY JOURNAL; CASE REPORT; DRUG-INDUCED LIVER INJURY; FEMALE; ORAL DRUG ADMINISTRATION; PATHOLOGY; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED, 80 AND OVER; ANTITHROMBINS; BENZIMIDAZOLES; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; PYRIDINES;

EID: 84887974391     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2013053     Document Type: Letter

References (10)

1. Thériaque. http://www.theriaque.org/
2. EMA. http://www.ema.europa.eu/
3. ANSM. Retrait du marché du melagatran AstraZeneca® 3 mg, solution injectable en seringue préremplie Exanta® 24 mg comprimé pelliculé (ximélagatran). Lettre aux prescripteurs du 14 février 2006. http://www.ansm.sante.fr/
4. ANSM. PGR Pradaxa 19 décembre 2008. http://www.ansm.sante.fr
5. Ezekowitz MD, Connolly S, Parekh A et al,. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin,compared with dabigatran. Am Heart J 2009 May; 157 (5): 805-10
6. Connolly SJ, Ezekowitz MD, Yusuf S et al,. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 Sep 17; 361 (12): 1139-51
7. Rochwerg B, Xenodemetropoulos T, Crowther M et al,. Dabigatran-induced acute hepatitis. Clin Appl Thromb Hemost 2012 Sep; 18 (5): 549-50
8. Stangier J, Rathgen K, Stähle H et al,. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010 Apr; 49 (4): 259-68
9. Kenne K, Skanberg I, Glinghammar B et al,. Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol In Vitro 2008 Apr; 22 (3): 730-46
10. Lee WM, Larrey D, Olsson R et al,. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005; 28 (4): 351-70